| 1.6912 0.071 (4.4%) | 10-23 11:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.53 | 1-year : | 2.97 |
| Resists | First : | 2.16 | Second : | 2.54 |
| Pivot price | 1.78 |
|||
| Supports | First : | 1.54 | Second : | 1.28 |
| MAs | MA(5) : | 1.71 | MA(20) : | 1.77  |
| MA(100) : | 2.01 |
MA(250) : | 2.89 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.3 |
D(3) : | 16.8 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 6.76 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HUMA ] has closed above bottom band by 40.8%. Bollinger Bands are 35.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.59 - 1.6 | 1.6 - 1.61 |
| Close: | 1.6 - 1.62 | 1.62 - 1.64 |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Fri, 17 Oct 2025
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - sharewise.com
Tue, 14 Oct 2025
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Tue, 07 Oct 2025
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering - Yahoo Finance
Tue, 07 Oct 2025
$60M Gross Proceeds: Humacyte Prices Oversubscribed Direct Offering of 28.4M Shares & Warrants - Stock Titan
Tue, 07 Oct 2025
Humacyte stock tumbles after $60 million registered direct offering - Investing.com
Tue, 07 Oct 2025
Humacyte: Shares Tank On Fundraising News - What You Need To Know (NASDAQ:HUMA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 187 (M) |
| Held by Insiders | 1.2529e+008 (%) |
| Held by Institutions | 16.9 (%) |
| Shares Short | 33,600 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0392e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 876 % |
| Return on Equity (ttm) | -50.2 % |
| Qtrly Rev. Growth | 818000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.2619e+007 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -105 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 107.1 |
| Dividend | 0 |
| Forward Dividend | 2.879e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|